Patents Examined by Charanjit Aulakh
  • Patent number: 11505551
    Abstract: The present disclosure relates to novel, scalable methods of making substituted tricyclic compounds that are useful to treat and/or prevent HBV and/or HBV-HDV infection and related conditions in a subject.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: November 22, 2022
    Assignee: Arbutus Biopharma Corporation
    Inventors: Shuai Chen, Bruce D. Dorsey, Dimitar B. Gotchev, Duyan Nguyen, Mahesh Kumar Pallerla, Ganapati Reddy Pamulapati
  • Patent number: 11505539
    Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: November 22, 2022
    Assignee: Ontario Institute for Cancer Research (OICR)
    Inventors: Methvin Isaac, Anh My Chau, Ahmed Mamai
  • Patent number: 11505556
    Abstract: The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 22, 2022
    Assignee: Xalud Therapeutics, Inc.
    Inventors: Raymond A. Chavez, Stephen Collins
  • Patent number: 11498896
    Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: November 15, 2022
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Edward Scolnick, Michelle Palmer, Luka Dordevic, Michael C. Lewis, Jennifer Q. Pan, Yan-Ling Zhang, Qihong Xu
  • Patent number: 11492352
    Abstract: The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound.
    Type: Grant
    Filed: June 29, 2019
    Date of Patent: November 8, 2022
    Assignees: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, SHIONOGI & CO., LTD.
    Inventors: Akihiro Ishii, Akihiko Sato, Makoto Kawai, Yoshiyuki Taoda
  • Patent number: 11491113
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: November 8, 2022
    Assignee: LABORATORIOS LEON FARMA SA
    Inventors: Philippe Perrin, Jose Luis Velada, Dominique Drouin
  • Patent number: 11495756
    Abstract: Provided are a compounds comprising a first ligand LA of
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: November 8, 2022
    Assignee: UNIVERSAL DISPLAY CORPORATION
    Inventors: Zhiqiang Ji, Pierre-Luc T. Boudreault, Wei-Chun Shih
  • Patent number: 11478486
    Abstract: The invention concerns a pharmaceutical combination of an inhibitor of the androgen receptor signaling pathway and of a p38 inhibitor for use in the treatment of prostate cancer in individuals wherein the prostate tumor cells express the AR-V7 variant androgen receptor protein or for preventing the occurrence of resistance in patients suffering from prostate cancer treated by an inhibitor of the androgen receptor signaling pathway. The invention further concerns a pharmaceutical composition comprising enzalutamide, abiraterone or apalutamide and a p38 inhibitor selected from LY2228820 and ARRY-614, and at least one pharmaceutically acceptable excipient.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: October 25, 2022
    Assignees: INSTITUT REGIONAL DU CANCER DE MONTPELLIER (ICM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER
    Inventors: CĂ©line Gongora, Diego Tosi
  • Patent number: 11482685
    Abstract: A compound of: is disclosed. In Formula IV, ring B and ring C are each independently a 5 or 6-membered carbocyclic or heterocyclic ring; A-B represents a bonded pair of carbocyclic or heterocyclic rings coordinated to a metal M via a nitrogen atom in ring A and an sp2 hybridized atom in ring B; A-C represents a bonded pair of carbocyclic or heterocyclic rings; M is a metal having an atomic number greater than 40; L? is a monoanionic bidentate ligand; m is the oxidation state of the metal M; and n is at least 1.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: October 25, 2022
    Assignee: UNIVERSAL DISPLAY CORPORATION
    Inventors: Chuanjun Xia, Bert Alleyne, Raymond C. Kwong, James Fiordeliso, Michael S. Weaver, Nasrin Ansari, Alan DeAngelis, Dinesh Rayabarapu, Vadim Adamovich
  • Patent number: 11479552
    Abstract: Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: October 25, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yu Yoshida, Yoichi Kita, Makoto Kotake, Keiichi Sorimachi, Toshiyuki Ohfusa, Takafumi Motoki, Taro Asaba
  • Patent number: 11478460
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: October 25, 2022
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • Patent number: 11479561
    Abstract: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: October 25, 2022
    Assignee: Cytokinetics, Incorporated
    Inventors: Ippei Sato, Takashi Kamikubo, Masanori Miura, Yuji Matsushima, Hiroaki Tanaka, Yasuhiro Shiina, Susumu Yamaki, Tomoyuki Saito, Hiroshi Kiyohara, Munemichi Ohe, Kayoko Mihara, Bradley Paul Morgan, Fady Malik, Scott Emile Collibee, Luke Ashcraft, Pu-Ping Lu, Jeffrey Michael Warrington, Marc Garard
  • Patent number: 11472803
    Abstract: The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: October 18, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Henrik Teller, Alexandros Vakalopoulos, Melissa Boultadakis Arapinis, Alexander Straub, Hanna Tinel, Markus Brechmann, Matthias Beat Wittwer, Maximillian Andreas Kullmann, Till Freudenberger, Thomas Mondritzki, Tobias Marquardt
  • Patent number: 11472796
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: October 18, 2022
    Assignee: CYTOKINETICS, INC.
    Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Wenyue Wang, Luke W. Ashcraft
  • Patent number: 11473123
    Abstract: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: October 18, 2022
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger Tung
  • Patent number: 11472827
    Abstract: Tetradentate and octahedral metal complexes suitable for use as phosphorescent or delayed fluorescent and phosphorescent emitters in display and lighting applications.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: October 18, 2022
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jian Li, Guijie Li
  • Patent number: 11466005
    Abstract: Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: October 11, 2022
    Assignee: JACOBIO PHARMACEUTICALS CO., LTD.
    Inventors: Haiquan Fang, Mingming Chen, Guiqun Yang, Yuelei Du, Yanping Wang, Tong Wu, Qinglong Li, Lei Zhang, Shaojing Hu
  • Patent number: 11464772
    Abstract: The invention provides methods for treating chronic and acute pain. For example, the invention provides methods of treating neuropathic and inflammatory pain.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: October 11, 2022
    Assignee: Blue Therapeutics, Inc.
    Inventors: Ajay Yekkirala, David Roberson, Michio Painter
  • Patent number: 11464771
    Abstract: The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: October 11, 2022
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Robert Cho, Jeffrey Alan Stafford
  • Patent number: 11459340
    Abstract: The present disclosure provides certain tri-substituted heteroaryl derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: October 4, 2022
    Assignee: NIKANG THERAPEUTICS, INC.
    Inventors: Jiping Fu, Yan Lou, Yigang He